Telmisartan in preventing epirubicin-induced myocardial disorders in patients with cancer who are receiving epirubicin
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2011
At a glance
- Drugs Telmisartan (Primary)
- Indications Heart failure; Myocardial disorders
- Focus Therapeutic Use
- 10 Oct 2010 Interim results presented at the 35th Congress of the European Society for Medical Oncology (ESMO).
- 04 Jun 2010 Interim results presented at the4 6th Annual Meeting of the American Society of Clinical Oncology.